Serabelisib

Small molecule

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 1/2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Endometrial Cancer
Phase 1/2 (2)
HR+/HER2- Metastatic Breast Cancer
Phase 1 (1)
Other / comorbidity
NCT05300048 · Faeth Therapeutics
2022-04-22 – 2025-04-30 · Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation
What this study did

Competitive landscape

This drug's own stage for Endometrial Cancer: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Serabelisib: this drugPhase 2Small moleculePI3K alpha (inhibitor)Weak signalNo reviewed efficacy summary in this indication
DostarlimabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT03914612: PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023).
Fruquintinib (Fruzaqla / Elunate)Phase 3Small moleculeVEGFR1/2/3not yet gradedNo reviewed efficacy summary in this indication
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
Puxitatug SamrotecanPhase 3Antibody–drug conjugateB7-H4not yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SelinexorPhase 3Small moleculeXPO1 (exportin-1)not yet gradedNo reviewed efficacy summary in this indication
Sotiburafusp AlfaPhase 3Multispecific antibodyPD-L1 / VEGFnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
IMGN-151Phase 1Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Serabelisib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
September 2028 (1)
Phase 2Endometrial CancerRecruiting
Est. primary completion 2028-09 · NCT06463028 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-05 · NCT07558733 · CT.gov ↗
What to watch

See the full readout calendar ↗